These genetically modified mice develop progressive AD-type pathologies such as age-related elevated levels of Aβ and amyloid plaque deposition in the hippocampus and neocortex, tau hyperphosphorylation and variable synapse loss. This evidence concerns the gene MAPT and Alzheimer disease.